Trial Profile
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Ibrutinib; Idelalisib
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 23 Feb 2023 Status changed from active, no longer recruiting to completed.
- 10 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 24 Feb 2021 Planned End Date changed from 15 Jan 2022 to 15 Jan 2023.